ARCT Insider Trading

Insider Ownership Percentage: 16.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,294,510.00

Arcturus Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Arcturus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Arcturus Therapeutics Share Price & Price History

Current Price: $12.63
Price Change: Price Decrease of -0.1 (-0.79%)
As of 05/30/2025 05:00 PM ET

This chart shows the closing price history over time for ARCT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JulAugSepOctNovDecJanFebMarAprMay$12.63Closing price on 05/31/25:

SEC Filings (Institutional Ownership Changes) for Arcturus Therapeutics (NASDAQ:ARCT)

94.54% of Arcturus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARCT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$16Mbought$5.38MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500M$0$500MTotal InflowsTotal Outflows
Arcturus Therapeutics logo
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More on Arcturus Therapeutics

Today's Range

Now: $12.63
Low: $12.13
High: $12.83

50 Day Range

MA: $11.30
Low: $8.91
High: $12.91

52 Week Range

Now: $12.63
Low: $8.04
High: $45.00

Volume

1,003,031 shs

Average Volume

448,762 shs

Market Capitalization

$342.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.36

Who are the company insiders with the largest holdings of Arcturus Therapeutics?

Arcturus Therapeutics' top insider shareholders include:
  1. Pad Chivukula (COO)
  2. Keith C Kummerfeld (Insider)
Learn More about top insider investors at Arcturus Therapeutics.

Who are the major institutional investors of Arcturus Therapeutics?

Arcturus Therapeutics' top institutional investors include:
  1. ARK Investment Management LLC — 7.41%
  2. Sumitomo Mitsui Trust Group Inc. — 7.10%
  3. Nikko Asset Management Americas Inc. — 7.10%
  4. Vanguard Group Inc. — 6.45%
  5. Woodline Partners LP — 2.88%
  6. Goldman Sachs Group Inc. — 1.88%
Learn More about top institutional investors of Arcturus Therapeutics stock.

Which major investors are selling Arcturus Therapeutics stock?

Within the last quarter, ARCT stock was sold by these institutional investors:
  1. Sumitomo Mitsui Trust Group Inc.
  2. Nikko Asset Management Americas Inc.
  3. Caption Management LLC
  4. Jane Street Group LLC
  5. Woodline Partners LP
  6. Empire Life Investments Inc.
  7. Charles Schwab Investment Management Inc.
  8. Rafferty Asset Management LLC

Which major investors are buying Arcturus Therapeutics stock?

In the last quarter, ARCT stock was purchased by institutional investors including:
  1. Millennium Management LLC
  2. Vestal Point Capital LP
  3. ARK Investment Management LLC
  4. Acadian Asset Management LLC
  5. Vanguard Group Inc.
  6. Nuveen LLC
  7. Goldman Sachs Group Inc.
  8. Dynamic Technology Lab Private Ltd